Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 ~~days~~days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of RegulationS-T during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). ☒ Yes ☒☐ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, anon-accelerated filer, a smaller reporting company, or an emerging growth company. See ~~the~~ definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting ~~company”~~company,” and “emerging growth company” inRule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section ~~13(a)~~13 (a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of October 31, ~~2017,~~2019 was ~~48,766,664.~~58,268,567.

ChemoCentryx, Inc. (the Company) commenced operations in 1997. The Company is a clinical-stage biopharmaceutical company focused on developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. The Company’s principal operations are in the United States and it operates in one segment.

The financial information filed is unaudited. The Condensed Consolidated Financial Statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for the fair statement of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The December 31, ~~2016~~2018 Condensed Consolidated Balance Sheet was derived from audited financial statements. The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s financial statements and the notes thereto included in the Company’s ~~annual report~~Annual Report on Form10-K for the year ended December 31, ~~2016~~2018 filed with the Securities and Exchange Commission on March ~~14, 2017.~~11, 2019.

The preparation of financial statements in conformity with accounting principles generally accepted ~~accounting principles~~ in the United States ~~of America (U.S. GAAP)~~(GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.

The Company invests in a variety of financial instruments and, by its policy, limits the amount of credit exposure with any one issuer, industry or geographic area.

Accounts receivable are typically unsecured and are concentrated in the pharmaceutical industry and government sector. Accordingly, the Company may be exposed to credit risk generally associated with pharmaceutical companies and government funded entities. The Company has not historically experienced any significant losses due to concentration of credit risk.

As of December 31, 2016, accounts receivable excluded the $20.0 million cash commitment which is due from Vifor in December 2017 in connection with the CCX140 Agreement. See Note 7, “Collaboration and License Agreements” for a detailed discussion.

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents.

Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the sum of the weighted-average number of common shares outstanding and dilutive common stock equivalent shares outstanding for the period. The Company’s potentially dilutive common stock equivalent shares, which include incremental common shares issuable upon (i) the exercise of outstanding stock options and warrants, (ii) vesting of restricted stock units (RSUs) and restricted stock awards (RSAs), and (iii) the purchase from contributions to the 2012 Employee Stock Purchase Plan (the ESPP), (calculated based on the treasury stock method), are only included in the calculation of diluted net loss per share when their effect is dilutive.

For the nine months ended September 30, ~~2017~~2019 and ~~2016,~~2018, the following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:

Comprehensive loss comprises net loss and other comprehensive income (loss). For the periods presented, other comprehensive income (loss) consists of unrealized gains and losses on the Company’savailable-for-sale securities. For the nine months ended September 30, 2019, amounts reclassified from accumulated other comprehensive income (loss) to net loss for unrealized gains (losses) on available-for-sale securities were not significant, and were recorded as part of other income, net in the Condensed Consolidated Statements of Operations. For the three months ended September 30, 2019 and three and nine months ended September 30, ~~2017 and 2016,~~ 2018, there were no sales of investments and therefore there were no reclassifications ~~from accumulated~~.

The Company determines if an arrangement includes a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, accrued and other ~~comprehensive loss~~current liabilities and other non-current liabilities on the Company’s Condensed Consolidated Balance Sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The Company uses the incremental borrowing rate based on the information available at lease commencement date in determining the present value of future payments. The operating lease ROU asset also excludes lease incentives. The Company’s lease terms may include options to ~~net loss.~~extend or terminate the lease when it is reasonably certain that the Company will exercise any such options. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company has elected not to apply the recognition requirements for short-term leases. For lease agreements with lease and non-lease components, the Company generally accounts for them separately.

In ~~May 2014,~~February 2016, the Financial Accounting Standard Board (FASB) issued Accounting Standards Update (ASU)No. ~~2014-09,~~ Revenue from Contracts with Customers. The new standard’s core principle is that a reporting entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. On July 9, 2015, the FASB voted to delay the effective date of the new standard by one year. The standard would become effective for the Company beginning in the first quarter of 2018. Early application would be permitted in 2017. Entities would have the option of using either a full retrospective or a modified retrospective approach to adopt this new guidance. In 2016, the FASB updated the guidance for reporting revenue gross versus net to improve the implementation guidance on principal versus agent considerations, and for identifying performance obligations and the accounting of intellectual property licenses. In addition, the FASB introduced practical expedients and made narrow scope improvements to the new accounting guidance.

The Company currently plans to adopt the accounting standard update on January 1, 2018, using the modified retrospective approach. The cumulative effect of adopting the accounting standard update will be recorded to the Company’s accumulated deficit on January 1, 2018. The Company is currently analyzing its collaboration agreements to determine the differences in the accounting treatment under ASU~~No. 2014-09~~ compared to the current accounting treatment. During 2016, the Company entered into two license and collaboration agreements. The Company has primarily derived its revenues from license and collaboration agreements. The consideration the Company is eligible to receive under these agreements includes upfront payments, research and development funding, milestone payments, and royalties. Each license and collaboration agreement is unique and will need to be assessed separately under the five-step process under the new standard. The new revenue recognition standard differs from the current accounting standard in many respects, such as in the accounting for variable consideration and the measurement of progress toward completion of performance obligations. While the Company has not completed its ongoing assessment of the impact of adoption, the adoption of ASU~~No. 2014-09~~ ~~may have a material effect on its financial statements.~~

~~In February 2016, the FASB issued ASUNo. 2016-12,~~2016-02, Leases (Topic 842). The new standard requires ~~all lessees~~the Company to recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. On January 1, 2019, the Company adopted this new standard using the modified retrospective approach in accordance with Leases – Targeted Improvements (ASU No. 2018-11). The Company elected the package of practical expedients permitted under the transition guidance within ASU No. 2018-11, which among other things, allowed the Company to carry forward the historical lease classification of those leases in place as of January 1, 2019. Results for the three and nine months ended September 30, 2019 are presented under Topic 842. Prior period amounts have not been adjusted and continue to be reported in accordance with the Company’s historical accounting under previous lease guidance, ASC Topic 840, Leases (Topic 840).

The impact of the adoption of Topic 842 on the accompanying Condensed Consolidated Balance Sheet as of January 1, 2019 was as follows (in thousands):

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments. The new standard replaces the incurred loss impairment methodology under the current standard with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company will be required to use a forward-looking expected credit loss model for accounts receivable and other financial instruments. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. The new standard will be effective for the Company on January 1, 2020, with early adoption permitted on January 1, 2019. The Company is currently evaluating the impact of the adoption of this standard on its financial ~~statements. However, the Company expects~~statements and does not expect the adoption of this accounting guidance to ~~result in an increase in lease assets and~~have a ~~corresponding increase in lease liabilities~~material impact on ~~its balance sheets.~~

In ~~March 2016,~~June 2018, the FASB issued ASUNo. ~~2016-09,~~ ~~Improvements to Employee Share-Based Payment Accounting, which is intended to simplify several aspects of~~2018-07, Compensation – Stock Compensation (Topic 718). The new standard simplifies the accounting for share-based ~~payment award transactions, including~~payments to nonemployees by aligning it with the ~~income tax consequences, an option~~accounting for share-based payments to ~~recognize gross stock compensation expense~~employees, with ~~actual forfeitures recognized as they occur, as well as~~ certain classifications on the statement of cash flows. Under this guidance, on a prospective basis, companies will no longer record excess tax benefits and tax deficiencies from stock option exercises in additional~~paid-in~~ capital (APIC). Instead, they will record all excess tax benefits and tax deficiencies as income tax expense or benefit in the statement of operations. In addition, the guidance eliminates the requirement that excess tax benefits be realized before companies can recognize them. The ASU requires a cumulative-effect adjustment for previously unrecognized excess tax benefits in opening retained earnings in the annual period of adoption.exceptions. The Company adopted ~~ASUNo. 2016-09~~this new standard on January 1, 2017. Upon adoption, the Company recognized the excess tax benefit balance of $2.1 million as of January 1, 2017 as a deferred tax asset with a corresponding increase to the Company’s deferred tax asset valuation allowance. Additionally, as provided for under this new guidance, the Company elected to continue to estimate forfeitures.2019. The adoption of this ~~aspect of the~~accounting guidance did not have a material impact on the ~~Company’s~~consolidated financial statements.

In August 2018, the SEC adopted amendments to certain disclosure requirements in Securities Act Release No. 33-10532, Disclosure Update and Simplification. These amendments eliminated, modified, or integrated into other SEC requirements certain disclosure rules. Among the amendments was the requirement to present an analysis of changes in stockholders’ equity in the interim financial statements included in quarterly reports on Form 10-Q. The analysis, which can be presented as a footnote or separate statement, is required for the current and comparative quarter and year-to-date interim periods. The amendments became effective for the Company in its interim financial statements for the quarter ended March 31, 2019. The adoption of these SEC amendments did not have a material effect on the Company’s financial position, results of operations, cash flows or stockholders’ equity.

The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the consolidated financial statements as a result of future adoption.

The following table provides a reconciliation of cash, cash equivalents and restricted cash shown in the Condensed Consolidated Statements of Cash Flows (in thousands):

Restricted cash as of September 30, 2019 was held as collateral for stand-by letters of credit issued by the Company to its landlord in connection with the lease of the Company’s facility in San Carlos, California. See “Note 7. Commitments” for additional information of this lease.

The amortized cost and fair value of cash equivalents and investments at September 30, ~~2017~~2019 and December 31, ~~2016~~2018 were as follows (in thousands):

Cash equivalents in the tables above exclude cash of ~~$0.9~~$3.4 million and ~~$2.3~~$2.1 million as of September 30, ~~2017~~2019 and December 31, ~~2016,~~2018, respectively. Allavailable-for-sale securities held as of September 30, ~~2017~~2019 had contractual maturities of less than two years. There have been no significant realized gains or losses onavailable-for-sale securities for the periods presented. The Company applies the specific identification method to determine the cost basis of the securities sold. No significantavailable-for-sale securities held as of September 30, ~~2017~~2019 have been in a continuous unrealized loss position for more than 12 months. As of September 30, ~~2017,~~2019, unrealized losses onavailable-for-sale investments are not attributed to credit risk and are

considered to be temporary. The Company believes that it ismore-likely-than-not that investments in an unrealized loss position will be held until maturity or the recovery of the cost basis of the investment. The Company believes it has no other-than-temporary impairments on its securities because it does not intend to sell these securities and it believes it is not more likely than not that it will be required to sell these securities before the recovery of their amortized cost basis. To date, the Company has not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value.

The Company determines the fair value of financial assets and liabilities using three levels of inputs as follows:

Level 1—Inputs which include quoted prices in active markets for identical assets and liabilities.

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements ~~are~~were as follows ~~(in thousands)~~ as of September 30, ~~2017~~2019 and December 31, ~~2016:~~2018 (in thousands):

During the nine months ended September 30, ~~2017,~~2019, there were no transfers between Level 1 and Level 2 financial assets. When the Company uses observable market prices for identical securities that are traded in less active markets, the Company classifies its marketable debt instruments as Level 2. When observable market prices for identical securities are not available, the Company prices its marketable debt instruments usingnon-binding market consensus prices that are corroborated with observable market data; quoted market prices for similar instruments; or pricing models, such as a discounted cash flow model, with all significant inputs derived from or corroborated with observable market data.Non-binding market consensus prices are based on the proprietary valuation models of pricing providers or brokers. These valuation models incorporate a number of inputs, includingnon-binding and binding broker quotes; observable market prices for identical or similar securities; and the internal assumptions of pricing providers or brokers that use observable market inputs and, to a lesser degree, unobservable market inputs. The Company corroboratesnon-binding market consensus prices with observable market data using statistical models when observable market data exists. The discounted cash flow model uses observable market inputs, such as LIBOR-based yield curves, currency spot and forward rates, and credit ratings.

The carrying amount and estimated fair value of financial instruments not recorded at fair value at September 30, 2019 and December 31, 2018 were as follows (in thousands):

The fair value of the Company's long-term debt is estimated using the net present value of future debt payments, discounted at an interest rate that is consistent with market interest rates, which is a Level 2 input.

~~Bio-Techne Corporation, formerly Techne Corporation,~~On December 28, 2017 (the Closing Date), the Company entered into a Loan and Security Agreement with Hercules Capital, Inc. (Hercules) which the Company amended in December 2018, pursuant to which term loans in an aggregate principal amount of up to $50.0 million (the Credit Facility) were available to the Company in three tranches, subject to certain terms and conditions. As of September 30, 2019, the Company had borrowed $20.0 million under the Credit Facility and the remaining available amount had expired.

Advances under the Credit Facility bear an interest rate equal to the greater of either (i) 8.05% plus the prime rate as reported from time to time in The Wall Street Journal minus 4.75%, and (ii) 8.05%. At September 30, 2019, the interest rate on the outstanding borrowings under the Credit Facility was 8.30%. For advances made under the first and second tranches, the Company will make interest-only payments through July 1, 2021, and will then repay the principal balance and interest on the advances in equal monthly installments after the interest-only period and continuing through December 1, 2022.

The Company may prepay advances under the Credit Facility, in whole or in part, at any time, subject to a prepayment charge equal to: (a) 1.5% of the amount so prepaid, if such prepayment occurs during the second year following the Closing Date; and (b) 1.0% of the amount so prepaid, if such prepayment occurs after the second year following the Closing Date. The Credit Facility is ~~one~~secured by substantially all of the Company’s ~~principal stockholders.~~ assets, excluding intellectual property.

In ~~connection~~addition, Hercules has the right to participate, in an amount up to $2.0 million, in any subsequent equity financing broadly marketed to multiple investors in an amount greater than $20.0 million. The Credit Facility also includes customary affirmative restrictions on the payment of dividends and negative covenants, and events of default, the occurrence and continuance of which provide Hercules with the ~~Company’s initial public offering (IPO)~~right to demand immediate repayment of all principal and unpaid interest under the Credit Facility, and to exercise remedies against the Company and the collateral securing the Credit Facility. The Company was in ~~February 2012, Bio-Techne~~compliance with all loan covenants for all periods presented.

The Company will pay an end-of-term charge for each tranche it draws down, which will occur on the earliest of (i) the applicable tranche maturity date; (ii) the date that the Company prepays all of the outstanding principal under such tranche in full, or (iii) the date the loan payments are accelerated due to an event of default. For the first and second tranches, the end of term charge will be $0.9 million and $0.3 million, respectively.

In addition, the Company paid a commitment charge of 1% of the advances made under the Credit Facility, with a minimum charge of $162,500 paid on the Closing Date. Also, the Company reimbursed Hercules for costs incurred related to the Credit Facility. These charges were recorded as discounts to the carrying value of the loan and are amortized over the term of the loan using the effective interest method.

As of September 30, 2019, the Company had outstanding borrowings under the Credit Facility of $19.8 million, net of discounts of $0.2 million. Future minimum principal payments, which exclude the end of term charge, related to the Credit Facility as of September 30, 2019 are as follows (in thousands):

As described further in “Note 2. Summary of Significant Accounting Policies”, the Company adopted Topic 842 as of January 1, 2019. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.

In May 2004, the Company entered into a noncancelable operating lease for its current office and primary research facility located in Mountain View, California. The Company received a ~~warrant with~~discounted lease rate during the first year of the agreement. In August 2012, the Company entered into an amendment to the lease agreement for the same facility to extend the term through April 2019. In April 2017, the Company entered into a~~ten-year~~ second amendment to the lease agreement for the same facility to extend the term of the lease through April 2020. In May 2019, the Company entered into a third amendment to ~~purchase 150,000~~the lease agreement for the same facility to extend the term of the lease through April 2021.

The balance sheet classification of the Company’s operating lease liabilities was as follows (in thousands):

The component of lease costs, which was included in operating expenses in the Company’s Condensed Consolidated Statements of Operations, was as follows (in thousands):

Cash paid for amounts included in the measurement of lease liabilities for the nine months ended September 30, 2019 was $940,000 and was included in net cash used in operating activities in the Company’s Condensed Consolidated Statements of Cash Flows.

Future minimum lease payments under all noncancelable operating leases as of September 30, 2019 are as follows (in thousands):

As of September 30, 2019, the weighted-average remaining lease term was 1.6 years and the weighted-average operating discount rate used to determine the operating lease liability was 11.0%.

In July 2019, the Company entered into a ten-year operating lease for a 96,463 square foot facility in San Carlos, California to replace its current headquarters located in Mountain View, California, for which the lease expires in April 2021. Upon execution of the lease agreement, the Company provided the landlord an approximately $1.1 million security deposit in the form of a letter of credit. Subject to certain conditions pursuant to the lease, the Company anticipates the lease commencement date to occur in the third quarter of 2020 and monthly rent payments to begin in the second quarter of 2021. Following a six month period of discounted rent, the Company will pay an initial annual base rent at a rate of approximately $6.5 million, which is subject to scheduled 3% annual increases, plus certain operating expenses. The Company has been provided a tenant improvement allowance of $15.4 million plus an additional allowance of up to $4.8 million for the same. If the additional allowance is provided, such amount will be repaid by the Company as additional rent in equal monthly payments at a rate of 7% per annum through the initial term of the lease. The Company has the right to sublease the facility, subject to landlord consent. The Company also has the option to extend the lease for five years.

Vifor held 10,676,825 shares of the Company’s common stock ~~at an exercise price per share equal to $20.00 per share, or 200% of the IPO price of its common stock, which was outstanding~~ as of September 30, ~~2017.~~2019. The Company ~~had an~~has collaboration agreements with Vifor: the Avacopan Agreements and the CCX140 Agreements (each as described below). See “Note 2. Summary of Significant Accounting Policies – Concentration of Credit Risk” for additional information on accounts ~~payable~~receivable balance due ~~to Bio-Techne for the purchases of research materials of approximately $1,000 and $25,000 as of September 30, 2017 and December 31, 2016, respectively.~~from Vifor.

In May 2016, the Company entered into an exclusive collaboration and license agreement with Vifor ~~(International) Ltd. (Vifor)~~ pursuant to which the Company granted Vifor exclusive rights to commercialize avacopan in Europe and certain other markets (the Avacopan Agreement). Avacopan is the Company’s lead drug candidate for the treatment of patients with anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV) and other rare diseases. The Company retains control of ongoing and future development of avacopan (other than country-specific development in the licensed territories) and all commercialization rights to avacopan in the United States and China. The Avacopan Agreement also provided Vifor with an exclusive option to negotiate during 2016 a worldwide license agreement for one of the Company’s other drug candidates, CCX140, an ~~orally administered~~orally-administered inhibitor of the chemokine receptor known as CCR2.

In connection with the Avacopan Agreement, the Company received anon-refundable upfront payment of $85.0 million, comprising $60.0 million in cash and $25.0 million in the form of an equity investment to purchase 3,333,333 shares of the Company’s common stock at a price of $7.50 per share.

In February 2017, Vifor and the Company expanded the Vifor territories under the Avacopan Agreement to include all markets outside the United States and China (the Avacopan Amendment). In connection with this February 2017 arrangement, the Company received a $20.0 million upfront payment for the expanded rights. In June 2018, Vifor and the Company further expanded the Vifor territories under the Avacopan Agreement to provide Vifor with exclusive commercialization rights in China (the Avacopan Letter Agreement, and together with the Avacopan Agreement and the Avacopan Amendment, the Avacopan Agreements). The Company retains control of ongoing and future development of avacopan (other than country-specific development in the licensed territories) and all commercialization rights to avacopan in the United States. In consideration for the Avacopan Letter Agreement, the Company received a $5.0 million payment for the expanded rights.

Upon achievement of certain regulatory and commercial milestones with avacopan, the Company will receive additional payments of up to $460.0 million under the Avacopan Agreement. In addition, the Company will receive royalties, with rates ranging from the low teens to the mid-twenties, on future potential net sales of avacopan by Vifor in the licensed territories. In December 2017, the Company achieved a $50.0 million regulatory milestone when the European Medicines Agency (EMA) validated the Company’s Conditional marketing authorisation (CMA) application for avacopan for the treatment of AAV.

The Company identified the following material promises under the Avacopan Agreements: (1) the license related to avacopan; (2) the development and regulatory services for the submission of the marketing authorisation application (MAA); and (3) an exclusive option to negotiate a worldwide license agreement for CCX140, which expired in 2016. The Company considered that the license has standalone functionality and is capable of being distinct. However, the Company determined that the license is not distinct from the development and regulatory services within the context of the agreement because Vifor is dependent on the Company to execute the development and regulatory activities in order for Vifor to benefit from the license. As such, the license is combined with the development and regulatory services into a single performance obligation. The exclusive option related to CCX140 is a separate performance obligation and the Company determined that its transaction price is not material. As such, the transaction price under this arrangement is allocated to the license and the development and regulatory services.

As of September 30, 2019, the transaction price of $153.0 million consists of the following:

$78.0 million upfront payment under the May 2016 Avacopan Agreement. Of the total $85.0 million upfront ~~consideration~~payment received under the May 2016 Avacopan Agreement, $7.0 million was ~~initially~~ allocated ~~as of June 30, 2016 as follows:~~

~~$7.0 million for~~to the issuance of 3,333,333 shares of the Company’s common stock valued at $2.10 per share, the closing stock price on the effective date of the agreement, May 9, 2016.

~~$12.5~~ The remaining $78.0 million ~~which~~ was creditable against an upfront fee payable by Vifor, should the parties enter into a worldwide license agreement for CCX140. The amount creditable decreased ratably into the fourth quarter of 2016. In October 2016, the amount creditable expired and was reclassifiedallocated to the ~~amortizable portion~~transaction price under this arrangement;

$20.0 million upfront payment under the February 2017 Avacopan Amendment;

$50.0 million regulatory milestone payment achieved upon the validation of ~~deferred revenue as discussed below.~~the Company’s CMA application by the EMA, for avacopan for the treatment of AAV in December 2017; and

~~The remaining~~$5.0 million non-refundable upfront ~~consideration of $65.5 million will be recognized over the estimated period of performance~~payment under the Avacopan ~~Agreement,~~Letter Agreement.

The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

The Company determined that the combined performance obligation will be performed over the duration of the contract, which ~~approximates 4.2 years, ending in June 2020. The deliverables under~~began on the ~~Avacopan Agreement consist~~effective date of ~~intellectual property licenses,~~May 9, 2016 and ends upon completion of development and regulatory ~~services for the submission of the Marketing Authorization Application (MAA).~~services. The Company ~~considered~~uses a cost-based input method to measure proportional performance and to calculate the ~~provisions~~corresponding amount of revenue to recognize. The Company believes this is the best measure of progress because other measures do not reflect how the Company transfers its performance obligation to Vifor. In applying the cost-based input method of revenue recognition, multiple-element arrangement guidance and concluded that the license and the development and regulatory activities for the submission of the MAA do not have stand-alone value because the rights conveyed to do not permit Vifor to perform all efforts necessary to use the Company’s technology to bring the compound through development and, upon regulatory approval, commercialization of the compound. Accordingly, the Company measures actual costs incurred relative to budgeted costs to fulfill the combined ~~these deliverables and allocated the remaining upfront consideration~~performance obligation. These costs consist primarily of ~~$65.5 million into~~third-party contract costs. Revenue is recognized based on actual costs incurred as a ~~single unit~~percentage of ~~accounting.~~

Following the October 2016 expiration of the $12.5 million potentially creditable towards a CCX140 license agreement, such amount was reclassified to the amortizable portion of deferred revenue, which continues to be recognized over the estimated period of performance under the Avacopan Agreement ending in June 2020.

~~In February 2017, Vifor and~~total budgeted costs as the Company expanded the Vifor territories under the Avacopan Agreement to include all markets outside the United States and China (the Avacopan Amendment). The Company retains control of ongoing and future development of avacopan (other than country-specific development in the licensed territories), and all commercialization rights to avacopan in the United States and China. In connection with this arrangement, the Company received a $20.0 million upfront cash commitment for the expanded rights, $10.0 million of which was received in February 2017. The remaining $10.0 million is due in February 2018 and is not reflected in accounts receivable as of September 30, 2017. The February 2017 Avacopan Amendment and the original May 2016 Avacopan Agreement are accounted for as a combined agreement. The February 2017 Avacopan Amendment did not represent a material modification given among other factors, there were no changes to the Company’s deliverables under the arrangement. As such, the additional upfront commitment of $20.0 million under the Avacopan Amendment will be recognized over the remaining estimated period ofcompletes its performance ~~ending in June 2020.~~ obligations.

For the three and nine months ended September 30, ~~2017,~~2019, the Company recognized ~~$6.2~~$8.8 million and ~~$18.2~~$20.9 million ~~respectively,~~ of collaboration and license revenue under the Avacopan ~~Agreement and the Avacopan Amendment,~~Agreements, respectively, as compared to ~~$4.1~~$7.6 million and ~~$6.8~~$28.8 million induring the same respective periods ended September 30, 2016. Upon achievement of certain regulatory and commercial milestones with avacopan, the Company will receive additional payments of up to $510.0 million under the Avacopan Agreement. In addition, the Company will receive royalties, with rates ranging from the low teens to the~~mid-twenties,~~ ~~on future potential net sales of avacopan by Vifor~~ in ~~the licensed territories.~~2018.

CCX140 Agreements

In December 2016, the Company entered into a second collaboration and license agreement with Vifor pursuant to which the Company granted Vifor exclusive rights to commercialize CCX140 (the CCX140 Agreement) in markets outside the ~~U.S.~~United States and ~~China,.~~China. CCX140 is an orally-administered inhibitor of the chemokine receptor known as CCR2. The Company retains marketing rights in the ~~U.S.~~United States and China, while Vifor has commercialization rights in the rest of the world. Pursuant to the CCX140 Agreement, the Company ~~will be~~is responsible for the clinical development of CCX140 in rare renal diseases and ~~will be~~is reimbursed for Vifor’s equal share of such development cost. Vifor retains an option to solely develop and commercialize CCX140 in more prevalent forms of chronic kidney disease (CKD). Should Vifor later exercise the CKD option, ~~ChemoCentryx~~the Company would receiveco-promotion rights infor CKD in the ~~U.S.~~

United States. Under the terms of the CCX140 Agreement, the Company received anon-refundable upfront ~~commitment~~payment of $50.0 million ~~$30.0 million~~in 2017.

In June 2018, the Company and Vifor entered into a letter agreement to expand Vifor’s rights to include the right to exclusively commercialize CCX140 in China (the CCX140 Letter Agreement). In connection with the CCX140 Letter Agreement, the Company received a non-refundable payment of ~~which was received in January 2017.~~$5.0 million. The ~~remaining $20.0 million, which is due on~~Company and Vifor also entered into an amendment to the ~~first anniversary~~CCX140 Agreement (the CCX140 Amendment, and together with the CCX140 Agreement and the CCX140 Letter Agreement, the CCX140 Agreements) to clarify the timing of certain payments with respect to development funding of the CCX140 ~~Agreement, was not reflected in accounts receivable as~~program by Vifor, and the Company received a non-refundable payment of September 30, 2017. The upfront commitment of $50.0 million will be recognized over the estimated period of performance under the CCX140 Agreement, which approximates 5.0 years, ending in December 2021. The deliverables under the CCX140 Agreement consist of intellectual property licenses, development and regulatory services for the submission of the MAA.$11.5 million. The Company ~~considered the provisions~~retains control of ~~the revenue recognition multiple-element arrangement guidance~~ongoing and ~~concluded that the license and the~~future development and regulatory activities for the submission of the MAA do not have stand-alone value because the rights conveyed to do not permit Vifor to perform all efforts necessary to use the Company’s technology to bring the compound through development and, upon regulatory approval, commercialization of the compound. Accordingly, the Company combined these deliverables and allocated the upfront consideration of $50.0 million into a single unit of accounting.

For the three and nine months ended September 30, 2017, the Company recognized $2.8 million and $8.0 million of collaboration and license revenue under the CCX140 Agreement, respectively, of which $2.5 million and $7.5 million were associated with the recognition of upfront commitment. The remaining amounts represented collaboration revenue derived from funding of CCX140 (other than country-specific development ~~services from Vifor.~~ in the licensed territories), and all commercialization rights to CCX140 in the United States.

Upon achievement of certain regulatory and commercial milestones with CCX140, the Company will receive additional payments of up to $625.0 million under the CCX140 Agreement. In addition, the Company will receive tiered royalties, with rates ranging from ten to themid-twenties, on net sales of CCX140 in the licensed territories.

~~Under~~The Company identified the ~~Avacopan Agreement and~~following material promises under the CCX140 ~~Agreement,~~Agreements: (1) the license related to CCX140; and (2) the development and regulatory services for the submission of the MAA. The Company considered that the license has standalone functionality and is capable of being distinct. However, the Company determined that ~~future contingent payments related to~~the license is not distinct from the development and regulatory ~~milestones meet~~services within the ~~definition~~context of ~~a substantive milestone under~~ the ~~accounting guidance. Accordingly, revenue for the achievement of these milestones will be recognized in the period when the milestone~~agreement because Vifor is ~~achieved. The Company will be eligible to receive contingent payments related to commercial milestones based~~dependent on the Company to execute the development and regulatory activities in order for Vifor to benefit from the license. As such, the license is combined with the development and regulatory services into a single performance of Vifor and these payments are not considered to be milestones under the accounting guidance. These contingent commercial milestone payments will be included in the allocation of arrangement consideration if and when achieved, resulting in an accounting treatment similar to the upfront payment. obligation.

As of September 30, ~~2017,~~2019, the transaction price of $113.6 million consists of the following:

$50.0 million upfront payment under the CCX140 Agreement;

$58.6 million of CCX140 development funding by Vifor; and

$5.0 million non-refundable upfront payment under the CCX140 Letter Agreement.

The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

The Company determined that the combined performance obligation will be performed over the duration of the contract, which began on the effective date of December 22, 2016 and ends upon completion of development and regulatory services. The Company uses a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. The Company believes this is the best measure of progress because other measures do not reflect how the Company ~~had not received any milestone payments~~transfers its performance obligation to Vifor. In applying the cost-based input method of revenue recognition, the Company measures actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. These costs consist primarily of third-party contract costs. Revenue is recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. For the three and nine months ended September 30, 2019, the Company recognized $1.8 million and $5.2 million of collaboration and license revenue under the ~~Avacopan Agreement or~~CCX140 Agreements, respectively, as compared to $1.5 million and $4.8 million during the ~~CCX140 Agreement.~~ same respective periods in 2018.

The ~~Company expects to recognize royalty revenue in~~following table presents the ~~period of sale~~contract assets and liabilities for all of the ~~related product, based on the underlying contract terms. The Avacopan Agreement and the CCX140 Agreement are accounted for as separate arrangements.~~

8. ~~Government Grant~~

In April 2016, the Company was awarded an Orphan Products Development grant by the U.S. Food and Drug Administration to support the clinical development of avacopan in the amount of $500,000, which was fully recognized and receivedCompany’s revenue contracts as of ~~September 30, 2017. The term of~~ the ~~grant expired in May 2017.~~ following dates (in thousands):

	September 30,			December 31,
	2019			2018
Contract asset:
Accounts receivable	$	—		$	2,058
Contract liability:
Deferred revenue		(110,708	)		(134,561	)

During the three and nine months ended September 30, ~~2017, the Company did not recognize any grant revenue. During the three and nine months ended September 30, 2016,~~2019, the Company recognized ~~$120,000~~the following revenue as a result of changes in the contract asset and ~~$295,000, respectively, of grant revenue.~~the contract liability balances (in thousands):

	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019
Revenue recognized in the period from:
Amount included in contract liability at the beginning of the period	$	10,581	$	25,910
Performance obligations satisfied (or partially satisfied) in previous periods	$	1,632	$	(2,155	)

9.	Stockholders’ Equity ~~Incentive Plans~~

Stock Options

During the nine months ended September 30, ~~2017,~~2019, the Company had the following ~~option~~ activities under its equity incentive plans:

   Outstanding Options
   Available for
Grant Shares Weighted Average
Exercise Price    Weighted
Average
Remaining
Contractual
Term
(Years)    Aggregate
Intrinsic Value
(in thousands)
Balance at December 31, 2016
   1,655,524 9,345,515 $ 7.72
Shares authorized
   1,900,000
Granted⁽¹⁾
   (1,914,238 ) 1,634,500 6.95
Exercised⁽²⁾
   40,208 (405,912 ) 5.85
Forfeited and expired⁽³⁾
   489,862 (476,528 ) 6.47



Balance at September 30, 2017
   2,171,356 10,097,575 $ 7.73    6.35    $ 10,544

		Available for Grant			Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Balance at December 31, 2018			1,708,516			10,720,200		$	8.39
	Shares authorized		2,000,000			—
	Granted ⁽¹⁾		(2,220,663	)		1,990,842			11.20
	Exercised ⁽²⁾		107,619			(915,355	)		6.01
	Forfeited and expired ⁽³⁾		767,863			(761,196	)		7.60
Outstanding at September 30, 2019			2,363,335			11,034,491		$	9.15		6.21	$	4,735,997
Vested and expected to vest, net of estimated forfeiture at September 30, 2019						10,686,306		$	9.10		6.12	$	4,713,658
Exercisable at September 30, 2019						7,396,982		$	8.65		4.91	$	4,087,458

(1)	The difference between shares granted in the number of shares available for grant and outstanding options represents the RSUs and RSAs granted for the period.

(2)	Shares presented as available for grant represents shares repurchased for tax withholding upon vesting of RSUs.

(3)	The difference between shares forfeited and expired in the number of shares available for grant and outstanding options represents the RSUs canceled ~~for~~during the period.

Restricted Stock

During the nine months ended September 30, ~~2017,~~2019, the activity for restricted stock is summarized as follows:

						Shares			Weighted Average Grant-Date Fair Value
				Weighted Average
				Grant-Date
	Shares			Fair Value
Balance at December 31, 2016		471,650		$	4.60
Balance at December 31, 2018							467,632		$	8.47
Granted		279,738			6.72		229,821			11.54
Vested		(185,842	)		4.26		(247,193	)		8.32
Canceled		(13,334	)		3.57		(6,667	)		10.86

Unvested at September 30, 2017		552,212		$	5.81

Unvested at September 30, 2019							443,593		$	10.10

Stock-based Compensation

Total stock-based compensation expense was ~~$1.9~~$2.9 million and ~~$6.8~~$8.5 million during the three and nine months ended September 30, ~~2017,~~2019, respectively, and ~~$1.8~~$2.8 million and ~~$6.5~~$8.0 million ~~respectively,~~ during the same periods ended September 30, ~~2016.~~2018, respectively. As of September 30, ~~2017, $9.6~~2019, $18.4 million, ~~$2.0~~$2.5 million and ~~$23,000~~$31,000 of total unrecognized compensation expenses associated with outstanding employee stock options, unvested restricted stock, and the ESPP, net of estimated forfeitures, were expected to be recognized over a weighted-average period of ~~2.52, 1.72,~~2.57, 1.33 and 0.12 years, respectively.

Equity Distribution Agreement

In December 2018, the Company entered into an Equity Distribution Agreement (EDA), pursuant to which the Company may offer and sell, from time to time, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $75.0 million. For the nine months ended September 30, 2019, the Company sold 6,491,196 shares of its common stock pursuant to its EDA for net proceeds of $73.3 million. These sales fully exhausted the amount available under the EDA. Accordingly, no further sales will be made under the EDA.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our financial statements and accompanying notes included in this Quarterly Report on Form 10-Q and the financial statements and accompanying notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2016,~~2018, filed with the Securities and Exchange Commission, or SEC, on March ~~14, 2017.~~11, 2019.

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “aim,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential” or “continue” or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs;

our ability to advance drug candidates into, and successfully complete, clinical trials;

the commercialization of our drug candidates;

the implementation of our business model, strategic plans for our business, drug candidates and technology;

the scope of protection we are able to establish and maintain for intellectual property rights covering our drug candidates and technology;

estimates of our expenses, future revenues, capital requirements and our needs for additional financing;

the timing or likelihood of regulatory filings and approvals;

our ability to maintain and establish collaborations or obtain additional government grant funding;

our financial performance; and

developments relating to our competitors and our industry.

These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those included in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2016,~~2018, filed with the SEC on March ~~14, 2017.~~11, 2019.

Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

~~ChemoCentryx~~^®,ChemoCentryx® and the ChemoCentryx logo ~~Traficet™ and Traficet-EN™~~ are our trademarks in the United States, the European Community, Australia and Japan. ~~EnabaLink~~^®EnabaLink® and ~~RAM~~^®RAM® are our trademarks in the United States. Each of the other trademarks, trade names or service marks appearing in this Quarterly Report on Form 10-Q belongs to its respective holder.

Unless the context requires otherwise, in this Quarterly Report on Form 10-Q the terms “ChemoCentryx,” “we,” “us” and “our” refer to ChemoCentryx, Inc., a Delaware corporation, and our ~~subsidiary~~subsidiaries taken as a ~~whole.~~whole unless otherwise noted.

Overview

ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of our drug candidates is designed to selectively ~~blocks~~block a specific ~~chemokine or~~ chemoattractant ~~receptors,~~receptor, leaving the rest of the immune system intact. Our drug candidates are small molecules, which are orally administered, ~~offering~~and, if approved, could address unmet medical needs, including improved efficacy, and offer significant quality of life benefits, since patients swallow a capsule or pill instead of having to visit a clinic for an infusion or undergo an injection.

In 2016, we executed on our strategy to form an alliance with a partner that could provide upfront ~~commitments~~fees and ~~milestones~~milestone payments to support the clinical development of our two leading ~~two~~ drug candidates, avacopan and CCX140, to registration and pay us royalties upon sales in international markets, while we develop our own commercial infrastructure to sell directly in the United States.

To help ~~us manage~~communicate the ~~wide array~~breadth of ~~opportunities,~~our drug discovery platform, we have segmented our pipeline into early stage and late stage ~~compounds.~~drug candidates.

Late Stage ~~Compounds~~Drug Candidates

We have chosen to focus initially on ~~kidney disease, particularly on rare~~orphan indications, where ~~orphan~~ drug candidates tend to enjoy a faster path to market and better reimbursement. Our leading drug candidates address areas of clear unmet need, where the current standard of care, or SOC, is insufficient to halt progression of the disease and/or where today’s treatment options come with serious side effects, such as those which accompany the prolonged use of steroids:

Avacopan (CCX168)~~—Complement~~ - Inhibition of Complement-Mediated Pathways in Orphan ~~and Rare~~ Diseases

Avacopan (formerly CCX168) is an orally-administered complement inhibitor targeting the C5a receptor, or C5aR, and is being developed for orphan ~~and rare~~ diseases, including 1)(i) anti-neutrophil cytoplasmic auto-antibody associated vasculitis, or AAV, a devastating autoimmune disease that ~~destroys~~damages blood vessels and can lead to kidney ~~failure; 2) atypical hemolytic uremic syndrome, or aHUS, a rare, life threatening disease;~~failure, pulmonary failure and 3)damage to other tissues; (ii) complement 3 glomerulopathy, or C3G, a debilitating ~~kidney~~ disease that can lead to kidney ~~failure.~~failure; and (iii) moderate to severe hidradenitis suppurativa, or HS, a chronic, inflammatory, debilitating skin disease characterized by recurrent, painful, nodules and abscesses, ultimately leading to the formation of draining fistulas (also known as sinus tracts) as well as scarring.

Avacopan has been granted orphan drug designation by the U.S. Food and Drug Administration, or FDA, for the treatment of AAV ~~aHUS~~ and C3G and by the European Medicines Agency, or EMA, for the treatment of C3G and microscopic polyangiitis and granulomatosis with polyangiitis, both forms of ~~AAV, and C3G.~~AAV. Additionally, avacopan ~~has been~~was granted PRIority MEdicines, or PRIME, designation from the EMA, to expedite its clinical development, and to potentially accelerate its marketing authorization.

Following completion of two randomized, placebo controlled Phase II clinical trials in patients with AAV, ~~the results of~~in which ~~demonstrated that~~ avacopan was ~~safe,~~ well-tolerated and provided effective steroid-free control of the disease, we launched the ADVOCATE Phase III ~~ADVOCATE~~ trial in December 2016. The FDA and the EMA concurred with the design of the study. ADVOCATE is a randomized, double-blind two-arm study ~~that is planned to enroll 300~~which enrolled 331 patients at ~~approximately~~over 200 sites in the United States, Canada, Europe, Australia, New Zealand and ~~New Zealand. We expect to complete patient~~Japan. Patient enrollment of the ADVOCATE Phase III ~~ADVOCATE~~trial was completed in September 2018 and we expect to report topline data from this trial in ~~mid-2018. We recently~~the mid-to-late fourth quarter of 2019. Additionally, we launched a registration-supporting clinical trial to study avacopan for the treatment of patients with C3G, the ACCOLADE trial, and ~~also plan to initiate~~initiated a large placebo-controlled Phase IIb clinical trial, the ~~same~~AURORA trial, for the treatment of patients with ~~aHUS~~moderate to severe HS. We expect to report topline data from both the ACCOLADE and AURORA trials in ~~2017; designed to potentially support registration of avacopan in these indications.~~2020.

~~CCX140—~~CCX140 - Chronic and ~~Rare~~Orphan Kidney Diseases

CCX140, is an orally-administered inhibitor of the chemokine receptor known as CCR2, has been in development for diabetic nephropathy, or DN, a form of chronic kidney disease, or CKD, and is now being developed for focal segmental glomerulosclerosis, or FSGS, a rare renal disease characterized by progressive ~~proteinuria—~~proteinuria, excess protein in the ~~urine—~~urine, and impaired renal function. CCX140 has been granted orphan drug designation by the FDA for the treatment of FSGS.

A global Phase II clinical trial of CCX140 in patients with DN met its primary endpoint by demonstrating that CCX140 given orally once daily added to ana SOC renin-angiotensin-aldosterone system inhibitor treatment resulted in a statistically significant reduction in proteinuria, beyond that achieved with SOC ~~alone.~~alone, with the most pronounced effect shown in the patients with highest levels of proteinuria. Based on the safety and efficacy data related to reduction in proteinuria observed in the Phase II trial in DN, we ~~plan to initiate in 2017 a~~launched two Phase II clinical ~~endpoint trial~~trials, the LUMINA trials, of CCX140 for the treatment of primary FSGS, with the LUMINA-2 trial being for patients with ~~FSGS,~~nephrotic range proteinuria and the LUMINA-1 trial being for patients with sub-nephrotic proteinuria, for which there are currently no FDA-approved treatments. Patient enrollment of LUMINA-1 was completed in August 2019, and we expect to report topline data in the first half of 2020.

~~Global~~ Kidney Health Alliance with Vifor

In May 2016, we announced a partnership, which we refer to as the Avacopan Agreement, with Vifor (International) Ltd., and/or its affiliates, or collectively, Vifor, a European-based world leader specializing in kidney ~~disease, for~~disease. While under this agreement we retained all rights to the ~~commercial~~United States and China, we granted Vifor exclusive commercialization rights to avacopan in Europe and certain other international ~~markets,~~markets. In December 2016, we entered into an additional agreement with Vifor, which we refer to as the ~~Avacopan Agreement. We expanded our partnership with Vifor in December 2016 with an additional deal for~~CCX140 Agreement, relating to CCX140, our other late stage drug ~~candidate,~~candidate. Under the CCX140 ~~whereby~~Agreement, we again retained all rights to the United States and China and we granted Vifor exclusive worldwide commercialization rights outside of the United States and ~~China, which we refer to as the CCX140 Agreement; and in~~China. In February 2017, we announced a further ~~deal~~agreement with Vifor ~~for avacopan~~ that harmonized the geographic commercialization rights underlying the agreements for both drug candidates, which we refer to as the Avacopan Amendment. In June 2018, we entered into additional agreements with Vifor to further expand Vifor’s exclusive commercialization rights to include China under the Avacopan Agreement (the Avacopan Letter Agreement) and the CCX140 Agreement (the CCX140 Letter Agreement).

We have secured ~~$155~~$215 million in upfront cash ~~payments~~ and ~~commitments, plus substantial potential~~ milestone payments pursuant to our agreements with ~~Vifor.~~Vifor and are eligible for additional substantial milestone payments. Through our alliance, we maintain the ~~commercial~~commercialization rights ofto avacopan and CCX140 in the United States, ~~and China,~~ and also retain control of the clinical development programs for ~~rare~~orphan renal disease. Vifor ~~gains~~gained the ~~commercial~~exclusive commercialization rights for all other international markets, and ~~will~~is obligated to pay us tiered royalties, with rates ranging from ten to the mid-twenties, on potential net sales.

At a future time defined in the ~~contract,~~CCX140 Agreement, Vifor has an option to solely develop and commercialize CCX140 in more prevalent forms of CKD. Should Vifor later exercise the CKD option, we would receive co-promotion rights for CKD in the United States, and we estimate that the clinical development and registration process for CKD would end at approximately the same time as Orphan Drug exclusivity.

Early Stage ~~Compounds~~Drug Candidates

While ~~the science has led us to focus~~we have focused initially on kidney ~~disease,~~and dermatological diseases, our ~~targeted blocking system~~ target-specific and selective approach designed to stop the spread of inflammatory disease-inducing cells shows promise in other disease areas. Over time we plan to bring forward drug candidates to treat ~~other~~a range of inflammatory and autoimmune disorders, as well as cancer, where our drug candidate CCX872 has shown promise in a Phase IIb trial for ~~non-operable~~advanced pancreatic cancer. ~~Our~~We expect that our ability to do so will grow as we increase our scale and to the extent that we start to earn revenues and royalties from the commercialization of our late stage kidney disease franchise.

Since commencing our operations in 1997, our efforts have focused on research, development and the advancement of our drug candidates into and through clinical trials. As a result, we have incurred significant losses. We have funded our operations primarily through the sale of convertible preferred and common stock, contract revenue under our collaborations, government contracts and grants and borrowings under equipment financing arrangements.

As of September 30, ~~2017,~~2019, we had an accumulated deficit of ~~$328.9~~$414.5 million. We expect to continue to incur net losses as we develop our drug candidates, expand clinical trials for our drug candidates currently in clinical development, expand our research and development activities, expand our systems and facilities, seek regulatory approvals and engage in commercialization preparation activities in anticipation of FDA approval of our drug candidates. In addition, if a product is approved for commercialization, we will need to expand our organization. Significant capital is required to launch a product and many expenses are incurred before revenues are received. We are unable to predict the extent of any future losses or when we will become profitable, if at all.

~~JOBS Act~~

In April 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an emerging growth company can utilize the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for implementing new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to delay such adoption of new or revised accounting standards, and as a result, we may not implement new or revised accounting standards on the relevant dates on which adoption of such standards is required for other companies.

Subject to certain conditions set forth in the JOBS Act, as an emerging growth company, we intend to rely on certain of these exemptions, including without limitation, providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404 and implementing any requirement that may be adopted regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis). These exemptions will apply for a period of five years following the completion of our IPO although if the market value of our common stock that is held by nonaffiliates exceeds $700 million as of any June 30 before that time, we would cease to be an emerging growth company as of the following December 31.

Critical Accounting Policies and Significant Judgments and Estimates

We adopted Accounting Standards Codification Topic 842, Leases, on January 1, 2019, resulting in changes to our accounting policies for leases. There have been no material changes in significant judgments and estimates for our critical accounting policies during the nine months ended September 30, ~~2017,~~2019, as compared to those disclosed in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Significant Judgments and Estimates” in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2016,~~2018, filed with the SEC on March ~~14, 2017.~~11, 2019.

Results of Operations

Revenue

We have not generated any revenue from product sales. For the periods presented, our revenues were derived from ~~(i) the recognition of the upfront payments~~collaboration and license revenue related to the Avacopan Agreement ~~Avacopan Amendment~~ and ~~CCX140 Agreement; (ii) collaboration revenue under~~ the CCX140 Agreement, in each case, as amended, and ~~(iii) grant revenue from~~ the ~~FDA Orphan Products Development grant to support the clinical development of avacopan for the treatment of patients with AAV.~~related letter agreements. Total revenue for the three and nine month periods ended September 30, 2019, as compared to the same periods in the prior year, ~~were~~was as follows (in thousands):

   Three Months Ended
September 30,    Nine Months Ended
September 30,
   2017 2016    2017 2016
Collaboration and license revenue
   $ 9,029 $ 4,131    $ 26,196 $ 6,751
Grant revenue
   —   120    —   295




Total revenue
   $ 9,029 $ 4,251    $ 26,196 $ 7,046




Dollar increase
   $ 4,778    $ 19,150
Percentage increase
   112 %    272 %

	Three Months Ended September 30,					Nine Months Ended September 30,
	2019			2018		2019			2018
Collaboration and license revenue from related party	$	10,581		$	8,975	$	26,081		$	33,543
Total revenue	$	10,581		$	8,975	$	26,081		$	33,543
Dollar increase (decrease)	$	1,606				$	(7,462	)
Percentage increase (decrease)		18	%				-22	%

We use a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. In applying the cost-based input method of revenue recognition, we measure actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. These costs consist primarily of third-party contract costs. Revenue is recognized based on actual costs incurred as a percentage of total budgeted costs as we complete our performance obligations.

The ~~increases~~increase in revenue from ~~2016~~2018 to ~~2017~~2019 for the three ~~and~~month period was primarily attributable to a higher proportion of costs incurred relative to budget for the avacopan program. The decrease in revenue for the nine month ~~periods were~~period was primarily due ~~to; (i) amortization~~to the full enrollment of the upfront license fee commitments from Vifor pursuant to the Avacopan Agreement, Avacopan Amendment and CCX140 Agreement, as well as (ii) collaboration revenue for development services under the CCX140 Agreementavacopan ADVOCATE Phase III pivotal trial in ~~the 2017 periods. These increases were partially offset by a decrease in grant revenue from the FDA to support the clinical development of avacopan for the treatment of patients with AAV.~~2018.

Research and development expenses

Research and development expenses represent costs incurred to conduct basic research, the discovery and development of novel small molecule therapeutics, development of our suite of proprietary drug discovery technologies, preclinical studies and clinical trials of our drug candidates. We recognize all research and development expenses as they are incurred. These expenses consist primarily of salaries and related benefits, including stock-based compensation, third-party contract costs relating to research, formulation, manufacturing, preclinical study and clinical trial activities, laboratory consumables, and allocated facility costs. Total research and development expenses for the three and nine ~~months~~month periods ended September 30, ~~2017,~~2019, as compared to the same ~~period~~periods in the prior year, were as follows (in thousands):


	Three Months Ended September 30,					Nine Months Ended September 30,					Three Months Ended September 30,					Nine Months Ended September 30,
	2017			2016		2017			2016		2019			2018		2019			2018
Research and development expenses	$	12,315		$	8,389	$	36,614		$	28,696	$	18,096		$	15,135	$	51,074		$	47,636
Dollar increase	$	3,926				$	7,918				$	2,961				$	3,438
Percentage increase		47	%				28	%				20	%				7	%

The ~~increase in research and development expenses~~increases from ~~2016~~2018 to ~~2017~~2019 for the three and nine month ~~period was~~periods were primarily attributable to ~~higher in Phase III clinical development expenses due to the initiation and~~ patient enrollment of the avacopan ~~ADVOCATE~~AURORA Phase IIb clinical trial in patients with ~~AAV~~HS and ~~higher~~the two CCX140 LUMINA Phase II clinical ~~development expense due to start-up expenses related to the clinical trial of avacopan for the treatment of C3G. These increases were~~trials in patients with FSGS, partially offset by ~~lower Phase II expenses due to the completion of the avacopan~~

~~CLEAR~~decreases in research and CLASSIC clinical trials for the treatment of AAV in 2016. Decreased Phase I development expense was due to the completion of enrollment in the clinical trial for CCX872 in patients with advanced pancreatic cancer in 2016.

~~Research and development expenses increased from 2016 to 2017 for~~drug discovery expenses. For the nine month period, ~~primarily due to the initiation and patient enrollment of~~expenses for the avacopan ADVOCATE Phase III ~~ADVOCATE~~pivotal trial also decreased in ~~patients with AAV and start-up expenses related to~~2019 as the Phase II clinical trial of avacopan for the treatment of C3G. These increases were partially offset by lower Phase II clinical development expense primarily due to the completion of the avacopan CLEAR and CLASSIC clinical trials for the treatment of AAVstudy was fully enrolled in ~~2016 and lower Phase I development expense due to the completion of enrollment in the clinical trial for CCX872 in patients with advanced pancreatic cancer in 2016.~~2018.

The following table summarizes our research and development expenses by project (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016		2019		2018		2019		2018
Phase I	$	218	$	802	$	962	$	5,299	$	116	$	104	$	444	$	1,183
Phase II		3,760		1,192		6,476		9,780		6,997		3,536		18,273		11,554
Phase III		5,067		3,247		19,069		3,515		7,701		7,480		22,422		23,171
Research and drug discovery		3,270		3,148		10,107		10,102		3,282		4,015		9,935		11,728

Total R&D	$	12,315	$	8,389	$	36,614	$	28,696

Total research and development expenses									$	18,096	$	15,135	$	51,074	$	47,636

We track development expenses that are directly attributable to our clinical development candidates by phase of clinical development. Such development expenses include third-party contract costs relating to formulation, manufacturing, preclinical studies and clinical trial activities. We allocate research and development salaries, benefits or indirect costs to our development candidates and we have included such costs in research and development expenses. All remaining research and development expenses are reflected in “Research and drug discovery” which represents early stage drug discovery programs. Such expenses include allocated employee salaries and related benefits, stock-based compensation, consulting and contracted services to supplement our in-house laboratory activities, laboratory consumables and allocated facility costs associated with these earlier stage programs.

At any given time, we typically have several active early stage research and drug discovery projects. Our internal resources, employees and infrastructure are not directly tied to any individual research or drug discovery project and are typically deployed across multiple projects. As such, we do not maintain information regarding these costs incurred for our early stage research and drug discovery programs on a project specific basis. We expect our research and development expenses to increase as we advance our development programs further and increase the number and size of our clinical trials. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming. We or our partners may never succeed in achieving marketing approval for any of our drug candidates. The probability of success for each drug candidate may be affected by numerous factors, including preclinical data, clinical data, competition, manufacturing capability and commercial viability. Our strategy includes entering into additional partnerships with third parties for the development and commercialization of some of our independent drug candidates.

The successful development of our drug candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each drug candidate and are difficult to predict for each product. Given the uncertainty associated with clinical trial enrollments and the risks inherent in the development process, we are unable to determine the duration and completion costs of the current or future clinical trials of our drug candidates or if, or to what extent, we will generate revenues from the commercialization and sale of any of our drug candidates. We anticipate we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to the scientific and clinical success of each drug candidate, as well as ongoing assessment as to each drug candidate’s commercial potential. We will need to raise additional capital or may seek additional strategic alliances in the future in order to complete the development and commercialization of our drug candidates, including avacopan, CCX140 ~~CCX872~~ and ~~vercirnon.~~

CCX872.

General and administrative expenses

Total general and administrative expenses for the three and nine ~~months~~month periods ended September 30, ~~2017,~~2019, as compared to the same periods in the prior year, were as follows (in thousands):


	Three Months Ended September 30,					Nine Months Ended September 30,					Three Months Ended September 30,					Nine Months Ended September 30,
	2017			2016		2017			2016		2019			2018		2019			2018
General and administrative expenses	$	3,624		$	3,193	$	12,381		$	11,154	$	6,116		$	5,373	$	17,187		$	14,781
Dollar increase	$	431				$	1,227				$	743				$	2,406
Percentage increase		13	%				11	%				14	%				16	%

General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation and travel expenses, in executive, finance, business and corporate development and other administrative functions. Other general and administrative expenses include allocated facility-related costs not otherwise included in research and development expenses, legal costs of pursuing patent protection of our intellectual property, and professional fees for auditing, tax, and legal services.

The ~~increase~~increases from ~~2016~~2018 to ~~2017~~2019 for the three and nine month ~~period was~~periods were primarily due to higher ~~accounting related fees~~employee-related expenses, including those associated with ~~preparing to meet the requirements pursuant to the Sarbanes-Oxley Act of 2002. The increase from 2016 to 2017 for the nine month period was primarily due to~~our commercialization planning efforts, and higher ~~intellectual property related expenses and accounting related fees partially offset by lower travel expenses.~~professional fees.

We ~~expect~~anticipate that our general and administrative expenses will increase substantially in the future ~~as we expand our operating~~primarily due to pre-commercial activities and ~~incur additional expenses associated with preparing~~personnel costs to ~~meet~~support the ~~requirements pursuant to~~potential launch of avacopan for the ~~Sarbanes-Oxley Act~~treatment of ~~2002, including~~AAV in ~~connection with~~ the ~~expiration of our status as an emerging growth company, expected to occur in 2017.~~United States.

Other income, net

Other income, net primarily consists of interest income earned on our marketable securities. Total other income, net for the three and nine month periods ended September 30, 2019, as compared to the same periods in the prior year, was as follows (in thousands):


	Three Months Ended September 30,					Nine Months Ended September 30,					Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016		2017			2016		2019			2018			2019			2018
Interest income	$	350		$	259	$	1,003		$	506	$	1,311		$	1,066		$	3,850		$	2,471

Interest expense												(542	)		(423	)		(1,631	)		(778	)
Total other income, net	$	350		$	259	$	1,003		$	506	$	769		$	643		$	2,219		$	1,693

Dollar increase	$	91				$	497				$	126					$	526
Percentage increase		35	%				98	%				20	%					31	%

The increases in total other income, net from ~~2016~~2018 to ~~2017~~2019 for the three and nine month periods were primarily due to increased interest income resulting from higher cash and investment balances and rate of return on the investment portfolio in ~~2017~~2019, partially offset by increased interest expense due to additional borrowings under the ~~receipt of upfront payments totaling $125.0 million received from Vifor in connection~~loan and security agreement, or Credit Facility, with ~~the Avacopan Agreement, Avacopan Amendment and CCX140 Agreement.~~Hercules Capital, Inc., or Hercules.

Liquidity and Capital Resources

As of September 30, ~~2017,~~2019, we had approximately ~~$124.8~~$206.9 million in cash, cash equivalents, restricted cash and investments. Such amounts exclude $30.0 million in remaining upfront commitments in connection with the December 2016 CCX140 Agreement and February 2017 Avacopan Amendment, which are due on the first anniversary of these agreements. The following table shows a summary of our cash flows for the nine months ended September 30, ~~2017~~2019 and ~~2016~~2018 (in thousands):

	Nine Months Ended September 30,
	2019			2018
Cash provided by (used in)
Operating activities	$	(49,893	)	$	31,745
Investing activities	$	(19,132	)	$	(66,444	)
Financing activities	$	77,939		$	18,793

   Nine Months Ended
September 30,
       2017            2016
Cash provided by (used in)

Operating activities
   $ (917 )    $ 47,896
Investing activities
   4,473    (54,473 )
Financing activities
   2,381    7,621

Operating activities. Net cash used in operating activities was ~~$0.9~~$49.9 million for the nine months ended September 30, ~~2017,~~2019, compared to ~~$47.9 million~~net cash provided by operating activities of $31.8 million for the same period in ~~2016.~~2018. This ~~change~~decrease was primarily due to a higher net loss and changes in working capital ~~items. For~~items driven by the receipt of a $50.0 million milestone payment in connection with the Avacopan Agreement, a $10.0 million upfront commitment under the Avacopan Amendment, a $10.0 million of aggregate payments under the June 2018 Avacopan Letter Agreement and the CCX140 Letter Agreement and a $11.5 million payment for CCX140 development funding by Vifor in the 2018 period.

Investing activities. Net cash used in investing activities was $19.1 million for the nine months ended September 30, ~~2017, changes in working capital included the receipt of $30.0~~2019, compared to $66.4 million ~~of accounts receivable from the first installment of the upfront commitment under the CCX140 Agreement. For~~for the same period in ~~2016, changes in working capital included the receipt~~2018. The use of ~~$78.0 million, most of which~~cash was ~~included as deferred revenue, in connection with the Avacopan Agreement.~~

~~Investing activities.~~ ~~Net cash provided by or used in investing activities for periods presented~~ primarily ~~relate~~related to the purchases, ~~of investments~~sales and maturities of investments used to fund the day-to-day needs of our business. Following the March 2019 issuance of common stock through our Equity Distribution Agreement, or EDA, with Piper Jaffray & Co., we invested the majority of our net proceeds received in short and long-term investments. For the same period in 2018, the use of cash in investing activities presented represents the investment of funds received under the Avacopan Agreement, as amended, and the related letter agreements.

Financing activities. Net cash provided by financing activities was ~~$2.4~~$77.9 million for the nine months ended September 30, ~~2017,~~2019, compared to ~~$7.6~~$18.8 million for the same period in ~~2016.~~2018. Net cash provided by financing activities for the nine months ended September 30, 2019 included net proceeds of $73.3 million from the issuance of common stock under the EDA. Net cash provided by financing activities for both periods presented included proceeds from the exercise of stock options and stock purchases from ~~employee purchases of stock under~~contributions to our 2012 Employee Stock Purchase ~~Plan. For the nine months ended September 30, 2016, net~~Plan, and cash provided also included the receipt of $7.0 million in net proceeds from the issuance of 3,333,333 shares of our common stock in connection with the Avacopan Agreement. For the nine months ended September 30, 2017, cash used ~~for financing activities included $0.3 million (the value of withheld shares),~~ for tendered ChemoCentryx, Inc. common stock to satisfy employee tax withholding requirements upon vesting of restricted stock units.

In December 2017, we entered into the Credit Facility with Hercules, which provided for borrowings of up to $50.0 million in three tranches, subject to certain terms and conditions. Through September 30, 2019, we borrowed $20.0 million under the Credit Facility and the remaining $30.0 million of available borrowings expired as of September 30, 2019. We intend to use the net proceeds from the Credit Facility for general corporate purposes, which may include the repayment of debt and working capital. We were in compliance with all loan covenants as of September 30, 2019. See “Note 6. Long-term Debt” in the Notes to Condensed Consolidated Financial Statements included in Item 1 of this Quarterly Report on Form 10-Q for additional information regarding our borrowings.

As of September 30, ~~2017,~~2019, we had approximately ~~$124.8~~$206.9 million in cash, cash equivalents, restricted cash and investments, excluding the $30.0 million in remaining upfront commitments in connection with the December 2016 CCX140 Agreement and the February 2017 Avacopan Amendment, which are due on the first anniversary of these agreements.investments. We believe that our available cash, cash equivalents and investments will be sufficient to fund our anticipated level of operations for at least 12 months following our financial statement issuance date, November ~~7, 2017.~~4, 2019. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially.

Our future capital requirements are difficult to forecast and will depend on many factors, including:

the terms and timing of any other collaborative, licensing and other arrangements that we may establish;

the initiation, progress, timing and completion of preclinical studies and clinical trials for our drug candidates and potential drug candidates;

the number and characteristics of drug candidates that we pursue;

the progress, costs and results of our clinical trials;

the outcome, timing and cost of regulatory approvals;

delays that may be caused by changing regulatory approvals;

the cost and timing of hiring new employees to support continued growth;

the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;

the cost and timing of procuring clinical and commercial supplies of our drug candidates;

the cost and timing of establishing sales, marketing and distribution capabilities; and

the extent to which we acquire or invest in businesses, products or technologies.

Contractual Obligations and Commitments

There have been no material changes outside the ordinary course of our business to the contractual obligations we reported in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2016,~~2018, filed with the SEC on March ~~14, 2017.~~

11, 2019, other than as set forth below.

In May 2019, we entered into a third amendment to the existing lease agreement for our current headquarters in Mountain View. In July 2019, we entered into a new lease agreement (the Lease) in San Carlos, California to replace our current headquarters located in Mountain View, California. See “Note 7. Commitments” in the Notes to Condensed Consolidated Financial Statements included in Item 1 of this Quarterly Report on Form 10-Q for details of the amendment and the Lease.

Recent Accounting Pronouncements

See “Note 2. Summary of Significant Accounting Policies” in the ~~notes~~Notes to ~~condensed consolidated financial statements~~Condensed Consolidated Financial Statements included in Item 1 of this Quarterly Report on Form 10-Q for a full description of recently issued accounting pronouncements, including the respective expected dates of adoption and effects on our consolidated financial position and results of operations.

Item 3.

Quantitative and ~~Qualitative~~Qualitative Disclosures About Market Risk

Our market risks at September 30, ~~2017~~2019 have not changed significantly from those discussed in “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” of our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2016,~~2018, filed with the SEC on March ~~14, 2017.~~11, 2019, other than the following:

Advances under the Credit Facility bear an interest rate equal to the greater of (i) 8.05% plus the prime rate as reported from time to time in The Wall Street Journal minus 4.75%, and (ii) 8.05%. We are affected by market risk exposure primarily through the effect of changes in interest rates on amounts payable under the Credit Facility. At September 30, 2019, borrowings under the Credit Facility totaled $20.0 million with an interest rate of 8.30%. We are obligated to make interest-only payments through July 1, 2021, at which point we will then be obligated to repay the principal balance and interest on the advances in equal monthly installments after the interest-only period and continuing through December 1, 2022. If the amount outstanding under the Credit Facility remained at this level for an entire year and interest rate increased by 1%, our annual interest expense would increase by an additional $200,000. See “Note 6. Long-term Debt” in the Notes to Condensed Consolidated Financial Statements included in Item 1 of this Quarterly Report on Form 10-Q for additional information regarding our borrowings.

Item 4.

Controls and Procedures

Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures

As of September 30, ~~2017,~~2019, management, with the participation of our Disclosure Committee, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the ~~SEC’s~~Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial and Administrative Officer, to allow timely decisions regarding required disclosures.

Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. Based on this evaluation, our Chief Executive Officer and Chief Financial and Administrative Officer concluded that, as of September 30, ~~2017,~~2019, the design and operation of our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting during the three months ended September 30, ~~2017,~~2019, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

Not Applicable.

Item 1A.

Risk Factors

There have been no material changes to the risk factors included in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2016,~~2018, filed with the SEC on March ~~14, 2017.~~11, 2019, except the following:

Risks Related to Intellectual Property

We may become subject to third parties’ claims alleging infringement of patents and proprietary rights or seeking to invalidate our patents or proprietary rights, which would be costly, time consuming and, if successfully asserted against us, delay or prevent the development and commercialization of our products.

Intellectual property litigation and patent litigation in particular, is expensive, complex and lengthy and its outcome is difficult to predict. There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical and biotechnology industries. We may be subject to third-party claims in the future against us or our collaborators that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages, including treble damages and attorney’s fees if we are found to be willfully infringing a third party’s patents. Further, if a patent infringement suit were brought against us or our collaborators, we or they could be forced to stop or delay research, development, manufacturing or sales of the product or drug candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we or our collaborators may choose to seek, or be required to seek, a license from the third party and would most likely be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we or our collaborators were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or forced to redesign it, or to cease some aspect of our business operations if, as a result of actual or threatened patent infringement claims, we or our collaborators are unable to enter into licenses on acceptable terms. This could harm our business significantly. For example, for hidradenitis suppurativa, or HS, InflaRx GmbH holds patents regarding methods of use to treat HS with agents that inhibit C5a activities. While we believe that these patents may not be enforceable, may be invalidated, or may be limited in scope, such patents could potentially affect the use of avacopan to treat hidradenitis suppurativa. If we are unable to invalidate or challenge such patents for hidradenitis suppurativa, we may need to obtain a license to commercialize avacopan in that indication. Such a license, if necessary, could require us to make royalty or other material payments to InflaRx GmbH.

Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history and can involve other factors such as expert opinion. Our analysis of these issues, including interpretation of the relevance or the scope of claims in a patent or a pending application, determining applicability of such claims to our proprietary technologies or drug candidates, predicting whether a third party’s pending patent application will issue with claims of relevant scope, and determining the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our drug candidates. We do not always conduct independent reviews of pending patent applications and patents issued to third parties.

Additionally, patent applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain United States applications that will not be filed outside the United States can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our drug candidates or the use of our drug candidates. These applications may later result in issued patents, or the revival of previously abandoned patents, that will prevent, limit or otherwise interfere with our ability to make, use or sell our products. As a result, we may be unaware of third-party patents that may be infringed by commercialization of our drug candidates, and cannot be certain that we were the first to file a patent application related to a drug candidate or proprietary technology. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims.

In addition to infringement claims against us, third parties may challenge or infringe upon our existing or future patents. Proceedings involving our patents or patent applications or those of others could result in adverse decisions regarding the patentability of our inventions relating to our drug candidates, and/or the enforceability, validity or scope of protection offered by our patents relating to our drug candidates. Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material adverse effect on us. Or, if third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the U.S. Patent and Trademark Office to determine the priority of invention. We may also become involved in similar opposition proceedings in the European Patent Office regarding our intellectual property rights with respect to our products and technology.

The cost to us of any intellectual property litigation or other proceedings could be substantial. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Discovery proceedings in the United States might lead to the disclosure of some of our proprietary confidential information. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Intellectual property litigation and other proceedings may also absorb significant management and technical staff’s time which may materially and adversely impact our financial position and results of operations.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

Not Applicable.

Item 3.

Defaults Upon Senior Securities

Not Applicable.

Item 4.

Mine Safety Disclosures

Not Applicable.

Item 5.

Other Information

Not Applicable.

Item 6.

Exhibits

A list of exhibits is set forth on the Exhibit Index immediately ~~following~~preceding the signature page of this Quarterly Report on Form10-Q, and is incorporated herein by reference.

EXHIBIT INDEX


Exhibit Number		Description

~~31.1~~ 10.1		Lease Agreement, dated July 31, 2019, by and between the Registrant and ARE-SAN FRANCISCO NO. 63, LLC.

31.1		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following information from the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, ~~2017,~~2019, formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Comprehensive Loss, (iv) Condensed Consolidated Statements of Cash Flows, and (v) the Notes to Condensed Consolidated Financial Statements.

~~SIGNATURES~~SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		CHEMOCENTRYX, INC.
		~~CHEMOCENTRYX, INC.~~

Date: November ~~7, 2017~~4, 2019		/s/ Thomas J. Schall, Ph.D.

		Thomas J. Schall, Ph.D. President and Chief Executive Officer (Principal Executive Officer)

Date: November ~~7, 2017~~4, 2019		/s/ Susan M. Kanaya

		Susan M. Kanaya Executive Vice President, Chief Financial and Administrative Officer and Secretary (Principal Financial ~~and~~Officer)

Date: November 4, 2019		/s/ Pui San Kwan

		Pui San Kwan Vice President, Finance (Principal Accounting Officer)

2432


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	CCXI	The Nasdaq Stock Market LLC


	September 30,			December 31,			September 30,			December 31,
	2017			2016			2019			2018
Assets
Current assets:
Cash and cash equivalents	$	17,961		$	12,024		$	35,922		$	28,088
Short-term investments		102,603			105,740			135,011			148,896
Accounts receivable		530			30,205
Accounts receivable from related party								—			2,058
Prepaid expenses and other current assets		1,299			722			1,586			2,342

Total current assets		122,393			148,691			172,519			181,384
Property and equipment, net		970			905			1,588			1,536
Long-term investments		4,204			5,997			34,867			—
Operating lease right-of-use assets								1,993			—
Other assets		381			279			1,354			390

Total assets	$	127,948		$	155,872		$	212,321		$	183,310

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	1,353		$	671		$	937		$	966
Accrued liabilities		8,185			8,645
Deferred revenue		34,872			29,019

Accrued and other current liabilities								17,597			12,969
Deferred revenue from related party								36,819			50,461
Total current liabilities		44,410			38,335			55,353			64,396
Deferred revenue		46,027			67,547
Long-term debt, net								19,762			19,689
Non-current deferred revenue from related party								73,889			84,100
Othernon-current liabilities		214			101			1,455			387

Total liabilities		90,651			105,983			150,459			168,572
Commitments (Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding		—			—			—			—
Common stock, $0.001 par value, 200,000,000 shares authorized; 48,772,716 shares and 48,057,920 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively		49			48
Common stock, $0.001 par value, 200,000,000 shares authorized; 58,253,140 and 50,652,238 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively								58			51
Additionalpaid-in capital		366,187			356,966			475,869			389,398
Note receivable		(16	)		(16	)		(16	)		(16	)
Accumulated other comprehensive loss		(68	)		(50	)
Accumulated other comprehensive income (loss)								409			(198	)
Accumulated deficit		(328,855	)		(307,059	)		(414,458	)		(374,497	)

Total stockholders’ equity		37,297			49,889			61,862			14,738

Total liabilities and stockholders’ equity	$	127,948		$	155,872		$	212,321		$	183,310


	Three Months Ended						Nine Months Ended
	September 30,						September 30,						Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016			2019			2018			2019			2018
Net loss	$	(6,560	)	$	(7,072	)	$	(21,796	)	$	(32,298	)	$	(12,862	)	$	(10,890	)	$	(39,961	)	$	(27,181	)
Other comprehensive income (loss):
Unrealized gain (loss) onavailable-for-sale securities		45			(84	)		(18	)		36			56			48			607			(70	)

Comprehensive loss	$	(6,515	)	$	(7,156	)	$	(21,814	)	$	(32,262	)	$	(12,806	)	$	(10,842	)	$	(39,354	)	$	(27,251	)

	Common Stock					Additional Paid-In			Note			Accumulated Other Comprehensive			Accumulated			Total Stockholders'
	Shares			Amount		Capital			Receivable			Income (Loss)			Deficit			Equity
Balance as of December 31, 2018		50,652,238		$	51	$	389,398		$	(16	)	$	(198	)	$	(374,497	)	$	14,738
Net loss		—			—		—			—			—			(39,961	)		(39,961	)
Unrealized gain on investments		—			—		—			—			607			—			607
Issuance of common stock through Equity Distribution Agreement, net of issuance costs (Note 9)		6,491,196			6		73,270			—			—			—			73,276
Issuance of common stock under equity incentive and employee stock purchase plans		1,217,325			1		5,836			—			—			—			5,837
Repurchased shares upon vesting of restricted stock units for tax withholdings		(107,619	)		—		(1,174	)		—			—			—			(1,174	)
Employee stock-based compensation		—			—		8,359			—			—			—			8,359
Compensation expense related to options granted to consultants		—			—		180			—			—			—			180
Balance as of September 30, 2019		58,253,140		$	58	$	475,869		$	(16	)	$	409		$	(414,458	)	$	61,862

	Common Stock					Additional Paid-In			Note			Accumulated Other Comprehensive			Accumulated			Total Stockholders'
	Shares			Amount		Capital			Receivable			Loss			Deficit			Equity
Balance as of December 31, 2017		48,837,060		$	49	$	368,553		$	(16	)	$	(119	)	$	(289,200	)	$	79,267
Net loss		—			—		—			—			—			(27,181	)		(27,181	)
Adoption of ASC Topic 606, Revenue from Contracts with Customers		—			—		—			—			—			(47,331	)		(47,331	)
Unrealized loss on investments		—			—		—			—			(70	)		—			(70	)
Issuance of common stock under equity incentive and employee stock purchase plans		1,671,032			1		9,290			—			—			—			9,291
Repurchased shares upon vesting of restricted stock units for tax withholdings		(79,585	)		—		(473	)		—			—			—			(473	)
Employee stock-based compensation		—			—		7,246			—			—			—			7,246
Compensation expense related to options granted to consultants		—			—		723			—			—			—			723
Balance as of September 30, 2018		50,428,507		$	50	$	385,339		$	(16	)	$	(189	)	$	(363,712	)	$	21,472


Large accelerated filer	☐	☐	Accelerated filer	☒
Non-accelerated filer	☐
~~Non-accelerated~~ ~~filer~~		~~☐ (Do not check if a smaller reporting company)~~	Smaller reporting company	☐

Emerging ~~Growth Company~~growth company		☒		☐



PART I. FINANCIAL INFORMATION				Page

Item 1.		Financial Statements (Unaudited)				3

		Condensed Consolidated Balance Sheets – September 30, ~~2017~~2019 and December 31, ~~2016~~2018			3

		Condensed Consolidated Statements of Operations – Three and Nine Months Ended September 30, ~~2017~~2019 and ~~2016~~2018			4

		Condensed Consolidated Statements of Comprehensive Loss – Three and Nine Months Ended September 30, ~~2017~~2019 and ~~2016~~2018			5

	Condensed Consolidated Statements of Stockholders’ Equity – Three and Nine Months Ended September 30, 2019 and 2018	6

	Condensed Consolidated Statements of Cash Flows – Nine Months Ended September 30, ~~2017~~2019 and ~~2016~~2018			6	8

		Notes to Condensed Consolidated Financial Statements			7	9

Item 2.		Management’s Discussion and Analysis of Financial Condition and Results of Operations			14	21

Item 3.		Quantitative and Qualitative Disclosures About Market Risk			21	28

Item 4.		Controls and Procedures			21
			28

PART II. OTHER INFORMATION

Item 1.		Legal Proceedings			22	29

Item 1A.		Risk Factors			22	29

Item 2.		Unregistered Sales of Equity Securities and Use of Proceeds			22	30

Item 3.		Defaults Upon Senior Securities			22	30

Item 4.		Mine Safety Disclosures			22	30

Item 5.		Other Information			22	30

Item 6.		Exhibits			22
			30
~~SIGNATURES~~				24

EXHIBIT INDEX		31

SIGNATURES		23	32


	September 30, 2017		December 31, 2016
Vifor (International) Ltd.⁽¹⁾	$	530	$	30,000
U.S. Food and Drug Administration		—		205

	$	530	$	30,205

			Adjustments
	December 31, 2018		Due to the Adoption of Topic 842		January 1, 2019
Balance Sheet
Assets:
Operating lease right-of-use assets	$	—	$	1,301	$	1,301

Liabilities:
Operating lease liabilities:
Accrued and other current liabilities ⁽¹⁾		12,969		955		13,924
Other non-current liabilities ⁽²⁾		387		346		733


	September 30, 2017									September 30, 2019
	Amortized		Gross Unrealized					Fair		Amortized		Gross Unrealized				Fair
	Cost		Gains		Losses			Value		Cost		Gains		Losses		Value
Money market fund	$	17,098	$	—	$	—		$	17,098	$	32,547	$	—	$	—	$	32,547
U.S. treasury securities		46,687		—		(50	)		46,637		29,969		56		—		30,025
Commercial paper		32,066		—		—			32,066		18,408		—		—		18,408
Asset-backed securities											28,439		52		—		28,491
Corporate debt securities		28,122		—		(18	)		28,104		92,615		301		—		92,916

Totalavailable-for-sale securities	$	123,973	$	—	$	(68	)	$	123,905	$	201,978	$	409	$	—	$	202,387

Classified as:
Cash equivalents								$	17,098							$	32,509
Short-term investments									102,603								135,011
Long-term investments									4,204								34,867

Totalavailable-for-sale securities								$	123,905							$	202,387


	December 31, 2016									December 31, 2018
	Amortized		Gross Unrealized					Fair		Amortized		Gross Unrealized					Fair
	Cost		Gains		Losses			Value		Cost		Gains		Losses			Value
Money market fund	$	9,746	$	—	$	—		$	9,746	$	22,073	$	—	$	—		$	22,073
U.S. treasury securities		49,693		1		(22	)		49,672		23,013		—		(13	)		23,000
Commercial paper		16,183		—		—			16,183		45,683		—		—			45,683
Asset-backed securities											29,127		—		(34	)		29,093
Corporate debt securities		45,911		—		(29	)		45,882		55,228		—		(151	)		55,077

Totalavailable-for-sale securities	$	121,533	$	1	$	(51	)	$	121,483	$	175,124	$	—	$	(198	)	$	174,926

Classified as:
Cash equivalents								$	9,746								$	26,030
Short-term investments									105,740									148,896
Long-term investments									5,997

Totalavailable-for-sale securities								$	121,483								$	174,926

	December 31, 2018
Description	Level 1		Level 2		Level 3		Total
Money market fund	$	22,073	$	—	$	—	$	22,073
U.S. treasury securities		—		23,000		—		23,000
Commercial paper		—		45,683		—		45,683
Asset-backed securities		—		29,093		—		29,093
Corporate debt securities		—		55,077		—		55,077
Total assets	$	22,073	$	152,853	$	—	$	174,926

	Amounts
Year ending December 31:
Remaining of fiscal year 2019	$	—
2020		—
2021		6,381
2022		13,619
Total minimum payments		20,000
Less: amount representing debt discount		(238	)
Present value of remaining debt payments		19,762
Less: current portion		—
Non-current portion	$	19,762

	Operating leases
Year ending December 31:
Remaining of fiscal year 2019	$	376
2020		1,659
2021		579
Total minimum payments		2,614
Less: interest		(232	)
Present value of lease liabilities	$	2,382


				Outstanding Options
	Available for Grant			Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value (in thousands)
Balance at December 31, 2016		1,655,524			9,345,515		$	7.72
Shares authorized		1,900,000
Granted⁽¹⁾		(1,914,238	)		1,634,500			6.95
Exercised⁽²⁾		40,208			(405,912	)		5.85
Forfeited and expired⁽³⁾		489,862			(476,528	)		6.47

Balance at September 30, 2017		2,171,356			10,097,575		$	7.73		6.35	$	10,544